Saranas has closed a $4 million Series B financing round that will support final product testing and regulatory submission of the Saranas Early Bird system for FDA clearance and CE mark. Upon FDA clearance, the company also aims to initiate a clinical pilot with physicians in 2018. “This Series B financing reflects deep commitment to Saranas’ innovative approach for enhancing patient outcomes during vascular access procedures,” stated Zaffer Syed, President and CEO of Saranas.